[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366144-105":59,"doc-detail-366144-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","molecular-hybrids-of-thiazolidinone-bridging-redox-modulation-and-cancer-therapy","Molecular Hybrids of Thiazolidinone - Bridging Redox Modulation and Cancer Therapy","","Heterocyclic thiazolidinone derivatives are explored for therapeutic potential against cancers and oxidative stress-related disorders. The study evaluates previously synthesized TZDs-1, 6, and 7, and prepares a new derivative (TZD-5) confirmed by IR, 1H NMR, and 13C NMR through key carbonyl and imine functional groups. Antioxidant performance is measured by the DPPH assay, with TZD-5 showing strong activity (IC50 = 24.4 µg/mL) compared to ascorbic acid, attributed to a methoxy group introduced via N-alkylation. Cytotoxicity is assessed using the MTS assay on HFF-1, HepG2, and A549 cells at 24 and 48 h, revealing distinct cytotoxicity and selectivity profiles: TZD-1 and TZD-6 show dose-dependent effects with limited selectivity, TZD-5 has moderate selectivity favoring HepG2, and TZD-7 shows the most favorable selective cytotoxicity toward cancer cells with minimal effects on normal fibroblasts. Overall, TZD-5 and TZD-7 emerge as promising candidates for antioxidant and selective anticancer therapies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-hybrids-of-thiazolidinone-bridging-redox-modulation-and-cancer-therapy/366144/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-hybrids-of-thiazolidinone-bridging-redox-modulation-and-cancer-therapy/366144.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Which thiazolidinone derivatives were evaluated in the study?","Question",{"text":113,"@type":114},"Previously synthesized TZDs-1, 6, and 7 were examined, and a new derivative, TZD-5, was synthesized and characterized.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was antioxidant activity assessed, and what was the key result for TZD-5?",{"text":118,"@type":114},"Antioxidant activity was measured using the DPPH assay. TZD-5 showed the most potent effect (IC50 = 24.4 µg/mL), comparable to ascorbic acid.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the derivatives differ in cytotoxicity and selectivity toward cancer vs normal cells?",{"text":122,"@type":114},"TZD-1 and TZD-6 showed dose-dependent cytotoxicity on both cancerous (HepG2, A549) and normal (HFF-1) cells, limiting selectivity. TZD-5 showed moderate selectivity favoring HepG2, while TZD-7 demonstrated strong selective cytotoxicity toward cancer cell lines with minimal adverse effects on normal fibroblasts.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},366144,1790616961,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","Article  \nMolecular Hybrids of Thiazolidinone: Bridging Redox Modulation and Cancer Therapy  \nNourah A. Al Zahrani 1, Manal A. Alshabibi 2, Abrar A. Bakr 2, Fahad A. Almughem 2, Abdullah A. Alshehri 2, Huda A. Al-Ghamdi 1, Essam A. Tawfik 2,* and Laila A. Damiati 3, *  \nAcademic Editor: AthinaGeronikaki  \nReceived: 24 June 2025  \nRevised: 3 July 2025  \nAccepted: 6 July 2025  \nPublished: 7 July 2025  \nCitation: Zahrani, N.A.A.; Alshabibi, M.A.; Bakr, A.A.; Almughem, F.A.; Alshehri, A.A.; Al-Ghamdi, H.A.; Tawfik, E.A.; Damiati, L.A. Molecular Hybrids ofThiazolidinone:  \nBridging Redox Modulation and Cancer Therapy. Int. J. Mol. Sci. 2025, 26, 6529. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms26136529](10.3390/ijms26136529)  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Chemistry, College of Science, University of Jeddah, Jeddah 23218, Saudi Arabia; [nalzahrani2@uj.edu.sa](nalzahrani2@uj.edu.sa) (N.A.A.Z.); [halgamdi4@uj.edu.sa](halgamdi4@uj.edu.sa) (H.A.A.-G.)  \n2 Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia; [malshabibi@kacst.gov.sa](malshabibi@kacst.gov.sa) (M.A.A.);  \n[aabakr@kacst.gov.sa](aabakr@kacst.gov.sa) (A.A.B.); [falmughem@kacst.gov.sa](falmughem@kacst.gov.sa) (F.A.A.); [abdualshehri@kacst.gov.sa](abdualshehri@kacst.gov.sa) (A.A.A.)  \n3 Department of Biological Science, College of Science, University of Jeddah, Jeddah 23218, Saudi Arabia  \n* Correspondence: etawfik@kacst.gov.sa (E.A.T.); ladamiati@uj.edu.sa (L.A.D.)  \nAbstract  \nHeterocyclic compounds have shown that they hold significant therapeutic activities, highlighting the importance of discovering and developing novel candidates against cancers, infections, and oxidative stress-associated disorders. In this study, we demonstrated the biological activity of our previously synthesized thiazolidinone derivatives (TZDs-1, 6, and 7) . Furthermore, we synthesized and structurally characterized a new derivative (TZD-5) using IR, 1H NMR, and 13C NMR spectroscopy, confirming the presence of its key functional groups, namely, carbonyl and imine. Their antioxidant activity was assessed through the DPPH assay, with TZD-5 showing the most potent effect (IC 50 = 24.4 µg/mL), comparable to ascorbic acid, an effect attributed to the methoxy group introduced via N-alkylation. Cytotoxicity was evaluated using the MTS assay on normal (HFF-1) and cancerous (HepG2 and A549) cell lines at two time points: 24-and 48 h exposure. Our findings highlight clear differences in cytotoxicity and selectivity among the tested thiazolidinone derivatives. TZD-1 and TZD-6 demonstrated significant, dose-dependent cytotoxic effects on both cancerous (HepG2 and A549) and normal (HFF-1) cell lines, thus limiting their therapeutic potential due to insufficient selectivity. TZD-5 exhibited moderate selectivity with higher susceptibility for HepG2 cells compared to normal cells. Notably, TZD-7 showed the most favorable cytotoxic profile, demonstrating strong selective cytotoxicity toward cancer cell lines with minimal adverse effects on normal fibroblasts. Overall, the results highlight TZD-5 and TZD-7 as promising candidates for antioxidant and selective anticancer therapies.  \nKeywords: thiazolidinone derivatives; biological activity; antioxidant properties; chemical synthesis; electron-donating groups  \n1. Introduction  \nAntioxidants play a crucial role in mitigating oxidative stress, which results from an imbalance between reactive oxygen species (ROS) production and the body’s ability to neutralize these harmful molecules. Oxidative stress has been implicated in the pa","cbCain7NFwGhWnkM","https://ap.wps.com/l/cbCain7NFwGhWnkM","pdf",4226982,17,"English","# Introduction\n## Antioxidants and oxidative stress\n## Thiazolidinone structure and biological relevance\n## Overview of thiazolidinone derivatives (Figure 1)","[{\"question\":\"Which thiazolidinone derivatives were evaluated in the study?\",\"answer\":\"Previously synthesized TZDs-1, 6, and 7 were examined, and a new derivative, TZD-5, was synthesized and characterized.\"},{\"question\":\"How was antioxidant activity assessed, and what was the key result for TZD-5?\",\"answer\":\"Antioxidant activity was measured using the DPPH assay. TZD-5 showed the most potent effect (IC50 = 24.4 µg/mL), comparable to ascorbic acid.\"},{\"question\":\"How did the derivatives differ in cytotoxicity and selectivity toward cancer vs normal cells?\",\"answer\":\"TZD-1 and TZD-6 showed dose-dependent cytotoxicity on both cancerous (HepG2, A549) and normal (HFF-1) cells, limiting selectivity. TZD-5 showed moderate selectivity favoring HepG2, while TZD-7 demonstrated strong selective cytotoxicity toward cancer cell lines with minimal adverse effects on normal fibroblasts.\"}]","Molecular Hybrids of Thiazolidinone - Bridging Redox Modulation and Cancer Therapy | PDF",1790163972,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cf29040a1dc482f88306e5f5b9389b2.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44e700bf3a76b0abfd5d8b7e945eadf5.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cffa370bb5195bf25f592726b7bb59ba.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4f48a2c4f1576e0f391b397f6de80aa.webp",980,1385]